{"id":496096,"date":"2020-07-15T13:42:01","date_gmt":"2020-07-15T13:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496096"},"modified":"2020-07-15T13:42:01","modified_gmt":"2020-07-15T13:42:01","slug":"vernal-keratoconjunctivitis-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_496096.html","title":{"rendered":"Vernal Keratoconjunctivitis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vernal Keratoconjunctivitis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Vernal Keratoconjunctivitis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>\u201cVernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030\u201d.<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on &ldquo;<strong>Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030<\/strong>&rdquo;.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-market\">Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030<\/a><\/strong>&rdquo; report delivers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered: <\/strong>The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, MEA (Saudi Arabia, Egypt), China and Russia<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal Keratoconjunctivitis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The market size of VKC in the global market was <strong>USD 307.89 million<\/strong> in 2017.<\/li>\n<li>According to the World Allergy Organization, males are more frequently affected than females, with a ratio of 3:1. The disease usually begins before the age of 10 years and remits at the time of puberty, although the age of affected individuals ranges from 3 to 25 years of age.&nbsp;<\/li>\n<li>A study published by (Samah M.M Ahmed et al, 2019), the prevalence of VKC among the studied children was 3.9%.&nbsp; VKC is fairly common among children in Menoufia Governorate as part of the North African region.<\/li>\n<li>Vernal Keratoconjunctivitis may represent 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Benefits of Vernal Keratoconjunctivitis Market Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Vernal Keratoconjunctivitis market report provides an in-depth analysis of Vernal Keratoconjunctivitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/p>\n<p style=\"text-align: justify;\">&bull; The Vernal Keratoconjunctivitis market report will help in developing business strategies by understanding the Vernal Keratoconjunctivitis Market trends &amp; developments, key players and future market competition that will shape and drive the Vernal Keratoconjunctivitis market in the upcoming years.<\/p>\n<p style=\"text-align: justify;\">&bull; The Vernal Keratoconjunctivitis market report covers Vernal Keratoconjunctivitis current treatment practices, emerging drugs, market share of the individual therapies in 7MM.<\/p>\n<p style=\"text-align: justify;\">&bull; The report provides a detailed assessment of the Vernal Keratoconjunctivitis market in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market\">https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>&ldquo;According To DelveInsight, Among the MENA regions, the highest market share is contributed by Egypt, followed by Saudi Arabia.&rdquo;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-market\">Vernal Keratoconjunctivitis (VKC)<\/a><\/strong> is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. It is an IgE\u2010 and T cell\u2010mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and mixed form. Large papillae of different shape and size, usually greater than 1 mm in diameter, on the upper tarsal conjunctiva, characterizes the tarsal form, while trantas&rsquo; dots and infiltrates on the limbus are the typical traits of the limbal form. The mixed form is characterized by the presence of both forms in the same eye.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal Keratoconjunctivitis Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\">The Vernal Keratoconjunctivitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal Keratoconjunctivitis market or expected to get launched in the market during the study period. The analysis covers Vernal Keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market\">https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The key players in Vernal Keratoconjunctivitis market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Antolimab (AK002): Allakos<\/li>\n<li>Talymus\/Tacrolimus: Senju Pharmaceutical<\/li>\n<li>Lodoxamide\/Alomide: Novartis Pharmaceuticals\/Alcon<\/li>\n<li>Verkazia\/Verkacia: Santen<\/li>\n<li>Nomacopan: Akari Therapeutics<\/li>\n<li>Bertilimumab\/iCo-008: iCo Therapeutics<\/li>\n<li>And others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Drugs Covered:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Antolimab (AK002)<\/li>\n<li>Talymus\/Tacrolimus<\/li>\n<li>Lodoxamide\/Alomide<\/li>\n<li>Verkazia\/Verkacia<\/li>\n<li>Nomacopan<\/li>\n<li>Bertilimumab\/iCo-008<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market\">https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Vernal Keratoconjunctivitis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\">4. Vernal Keratoconjunctivitis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Vernal Keratoconjunctivitis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Vernal Keratoconjunctivitis Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Vernal Keratoconjunctivitis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Vernal Keratoconjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Vernal Keratoconjunctivitis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Vernal Keratoconjunctivitis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Vernal Keratoconjunctivitis Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Vernal Keratoconjunctivitis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Vernal Keratoconjunctivitis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\">15. Vernal Keratoconjunctivitis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\">16. Vernal Keratoconjunctivitis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\">17. KOL Views on the Vernal Keratoconjunctivitis Market.<\/p>\n<p style=\"text-align: justify;\">18. Vernal Keratoconjunctivitis Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Vernal Keratoconjunctivitis Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Related Reports-<\/p>\n<p style=\"text-align: justify;\">Vernal Keratoconjunctivitis Epidemiology Forecast to 2030<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Vernal Keratoconjunctivitis &ndash; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Vernal Keratoconjunctivitis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vernal-keratoconjunctivitis-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vernal-keratoconjunctivitis-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cVernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030\u201d. DelveInsight has launched a new report on &ldquo;Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030&rdquo;. &nbsp; DelveInsight&rsquo;s &ldquo;Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030&rdquo; report delivers an in-depth &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_496096.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-496096","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496096"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496096\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}